Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
1.782
-0.048 (-2.63%)
Mar 9, 2026, 1:47 PM EDT - Market open
Company Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.
The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder.
It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders.
Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.
Adial Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jul 30, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Cary Claiborne |
Contact Details
Address: 4870 Sadler Road, Suite 300 Glen Allen, Virginia 23060 United States | |
| Phone | 804 487 8196 |
| Website | adial.com |
Stock Details
| Ticker Symbol | ADIL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001513525 |
| CUSIP Number | 00688A304 |
| ISIN Number | US00688A3041 |
| Employer ID | 80-0667150 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Cary John Claiborne MBA | Chief Executive Officer, President and Director |
| Tony Goodman | Chief Operating Officer and Director |
| Vinay Shah A.C.A., M.B.A. | Chief Financial Officer and Treasurer |
| John R. Martin J.D. | Chief Legal Officer |
| Andrew Taubman | Vice President of Corporate Development |
| Dr. Brigitte Robertson M.D. | Acting Chief Medical Officer |
| Abel Svitavsky CPA | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 6, 2026 | 8-K | Current Report |
| Mar 5, 2026 | 10-K | Annual Report |
| Mar 3, 2026 | 8-K | Current Report |
| Feb 24, 2026 | 8-K | Current Report |
| Feb 18, 2026 | SCHEDULE 13G | Filing |
| Feb 4, 2026 | 8-K | Current Report |
| Jan 6, 2026 | 8-K | Current Report |
| Jan 6, 2026 | DEF 14A | Other definitive proxy statements |
| Dec 23, 2025 | PRE 14A | Other preliminary proxy statements |
| Dec 19, 2025 | 424B5 | Filing |